LACTB and acute kidney injury: Ceftolozane/tazobactam, a combination cephalosporin with beta-lactamase inhibitor has a much lower AKI rate (3.8%) than polymyxin or aminoglycosides (adjusted OR 0.08, 95% CI 0.03–0.22) [124].